Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

103.85USD
22 May 2015
Change (% chg)

$-0.94 (-0.90%)
Prev Close
$104.79
Open
$103.96
Day's High
$104.56
Day's Low
$103.81
Volume
186,327
Avg. Vol
322,036
52-wk High
$105.75
52-wk Low
$84.17

NVS.N

Chart for NVS.N

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.43
Market Cap(Mil.): $280,359.81
Shares Outstanding(Mil.): 2,676.99
Dividend: 2.67
Yield (%): 2.57

Financials

  NVS.N Industry Sector
P/E (TTM): 24.00 37.22 39.17
EPS (TTM): 4.33 -- --
ROI: 10.83 16.24 15.58
ROE: 14.69 16.99 16.57
Search Stocks

Par does not infringe Novartis' patents for Alzheimer's patch - Fed. Circ.

- A U.S. appeals court has found that Par Pharmaceutical's copycat version of a patch for Alzheimer's disease-related dementia did not infringe two patents held by the Swiss drugmaker Novartis, helping to clear the way for regulatory approval of the generic drug.

21 May 2015

BRIEF-Novartis says lung disease drug studies show positive results

* Novartis says it saw positive results from two Phase III clinical trial programs for QVA149 and NVA237 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

20 May 2015

Novartis 'biosimilar' drug blocked by U.S. appeals court

- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

Novartis 'biosimilar' drug blocked by U.S. appeals court

- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

UPDATE 1-Novartis 'biosimilar' drug blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

07 May 2015

Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer patients.

07 May 2015

Rich Synageva M&A premium epitomizes appetite for orphan drugs

- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.

06 May 2015

CORRECTED-Rich Synageva M&A premium epitomizes appetite for orphan drugs

May 6 - The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.

06 May 2015

GSK scraps plan to list HIV drugs business and shields dividend

LONDON - GlaxoSmithKline scrapped plans to float its HIV drug business on Wednesday and promised to pay a steady dividend for three years, setting out long-term growth targets after the biggest shake-up in its 15-year history.

06 May 2015

Express Scripts unit to pay $60 mln over Novartis kickbacks, US says

NEW YORK - U.S. authorities said on Friday that a unit of Express Scripts Holding Co will pay $60 million to resolve claims that it participated in a kickback scheme with Novartis AG to boost sales of a drug that led to improper government reimbursements.

01 May 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $101.35 -1.07
Pfizer Inc. (PFE.N) $34.28 -0.08
Merck & Co., Inc. (MRK.N) $59.38 -0.72
Roche Holding Ltd. (ROG.VX) CHF277.90 -1.30
Abbott Laboratories (ABT.N) $49.03 -0.31
Sanofi SA (SASY.PA) €91.33 -0.97
AstraZeneca plc (AZN.L) 4,473.50p +48.50
GlaxoSmithKline plc (GSK.L) 1,464.50p +14.00
Eli Lilly and Co (LLY.N) $74.30 +0.03
Bristol-Myers Squibb Co (BMY.N) $68.30 -0.59

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Pechala's Reports
$1,000.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks